Literature DB >> 31209124

Evaluation of technologies approved for supplemental payments in the United States.

Timothy J Judson1, Sanket S Dhruva1,2, Rita F Redberg3,4.   

Abstract

Mesh：

Year:  2019        PMID： 31209124      PMCID： PMC6890455          DOI： 10.1136/bmj.l2190

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  24 in total

Review 1.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors:  Justin E Bekelman; Yan Li; Cary P Gross
Journal:  JAMA       Date:  2003 Jan 22-29       Impact factor: 56.272

2.  A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language.

Authors:  Tamar Krishnamurti; Steven Woloshin; Lisa M Schwartz; Baruch Fischhoff
Journal:  JAMA Intern Med       Date:  2015-11       Impact factor: 21.873

3.  Adoption and de-adoption of drotrecogin alfa for severe sepsis in the United States.

Authors:  Jeremy M Kahn; Tri Q Le
Journal:  J Crit Care       Date:  2015-12-11       Impact factor: 3.425

Review 4.  Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.

Authors:  Sanket S Dhruva; Lisa A Bero; Rita F Redberg
Journal:  JAMA       Date:  2009-12-23       Impact factor: 56.272

5.  US hospital payment adjustments for innovative technology lag behind those in Germany, France, and Japan.

Authors:  John Hernandez; Susanne F Machacz; James C Robinson
Journal:  Health Aff (Millwood)       Date:  2015-02       Impact factor: 6.301

6.  Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

Authors:  Livio Garattini; A Curto; K van de Vooren
Journal:  Value Health       Date:  2015-01-22       Impact factor: 5.725

7.  Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value.

Authors:  Corinna Sorenson; Michael Drummond; Lawton R Burns
Journal:  Health Aff (Millwood)       Date:  2013-04       Impact factor: 6.301

8.  Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation.

Authors:  Aaron S Kesselheim; Steven Woloshin; Wesley Eddings; Jessica M Franklin; Kathryn M Ross; Lisa M Schwartz
Journal:  JAMA       Date:  2016-04-12       Impact factor: 56.272

9.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

10.  Cardiac replacement with a total artificial heart as a bridge to transplantation.

Authors:  Jack G Copeland; Richard G Smith; Francisco A Arabia; Paul E Nolan; Gulshan K Sethi; Pei H Tsau; Douglas McClellan; Marvin J Slepian
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245
View more
  2 in total

1.  Insurance payment for artificial intelligence technology: Methods used by a stroke artificial intelligence system and strategies to qualify for the new technology add-on payment.

Authors:  Nick M Murray; Phillip Phan; Greg Hager; Andrew Menard; David Chin; Alvin Liu; Ferdinand K Hui
Journal:  Neuroradiol J       Date:  2022-01-06

2.  Brain-Computer Interfaces in Neurorecovery and Neurorehabilitation.

Authors:  Michael J Young; David J Lin; Leigh R Hochberg
Journal:  Semin Neurol       Date:  2021-03-19       Impact factor: 3.212
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.